Verastem Inc. (VSTM) is a biopharmaceutical company that focuses on developing and commercializing medicines to improve the lives of patients diagnosed with cancer. The company's lead product is Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma. Copiktra is approved in the United States for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Verastem is also developing other potential therapies for various cancers, including VS-6766, which is in clinical development for the treatment of various solid tumors.
Verastem Inc. (VSTM) is a biopharmaceutical company that focuses on developing and commercializing medicines to improve the lives of patients diagnosed with cancer. The company's lead product is Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma. Copiktra is approved in the United States for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Verastem is also developing other potential therapies for various cancers, including VS-6766, which is in clinical development for the treatment of various solid tumors.